Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466627 | 1.00 | OPRM1 (0.38) | OPRM1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL1898021 | 1.00 | OPRM1 (0.38) | OPRM1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL657906 | 0.78 | OPRM1 (0.38) | OPRM1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL1898020 | 0.78 | OPRM1 (0.38) | OPRM1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL3964870 | 0.78 | OPRM1 (0.38) | OPRM1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL2529125 | 0.78 | OPRM1 (0.38) | OPRM1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL4466623 | 0.78 | KCNA5 (0.38) | OPRM1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL9065797 | 0.78 | OPRM1 (0.38) | OPRM1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL7757727 | 0.74 | OPRM1 (0.45) | OPRM1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL8498802 | 0.74 | KCNA5 (0.46) | OPRM1TRPM8TRPA1KCNA5TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251289-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CANCER | CSIR (ZA) | 2011-10-13 | — | — | US | disclosed |
| EP-2321259-A2 | NEW COMPOUNDS FOR THE TREATMENT OF CANCER | CSIR (ZA) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009147632-A2 | NEW COMPOUNDS FOR THE TREATMENT OF CANCER | CSIR (ZA) | 2009-12-10 | — | — | WO | disclosed |
| EP-0579476-B1 | Cyanoacrylate adhesives with improved cured thermal properties | LOCTITE CORP (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0579476-A1 | Cyanoacrylate adhesives with improved cured thermal properties | LOCTITE CORPORATION (US) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251289-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CANCER | DUT, BAD, TYMS | OPRM1 1477/4885TRPM8 4185/4885TRPA1 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.